Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Samsung Biologics to acquire PolyPeptide Group

PRIVATEAug 27, 2026•about 3 hours ago

Acquiring Company

Samsung Biologics

Acquired Company

PolyPeptide Group

South KoreaSwitzerlandManufacturingBiotechnologyManufacturingBiotechnology

Description

Samsung Biologics has announced an all-cash offer to acquire PolyPeptide Group for CHF 1.46 billion. This acquisition will expand Samsung's portfolio into peptide-based therapeutics. The funding for this acquisition will be raised through a KRW 3 trillion rights offering. The move aims to enhance Samsung Biologics’ capabilities in meeting the global demand for diverse therapeutic modalities.

Company Information

Company

Samsung Biologics

Location

South Korea

About

Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. The company operates state-of-the-art, CGMP compliant facilities and has increased its biomanufacturing capacity to meet growing demand. With a commitment to innovative technologies and customized solutions, Samsung Biologics supports its clients' evolving needs in the biopharmaceutical sector. The company also has a presence in the U.S. and Europe to better collaborate with international clients.

Don't miss Samsung Biologics's next move

Get an email the moment Samsung Biologics makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Yong
Likely contact at this company
••••••••@••••••••

See Yong's verified email →

Kevin
Likely contact at this company
••••••••@••••••••

See Kevin's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Samsung Biologics's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired PolyPeptide Group?

PolyPeptide Group was acquired by Samsung Biologics, based in South Korea. The deal was reported on August 27, 2026. Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. Samsung Biologics is privately held and operates in Manufacturing.

When did Samsung Biologics acquire PolyPeptide Group?

Samsung Biologics's acquisition of PolyPeptide Group was reported on August 27, 2026. Samsung Biologics has announced an all-cash offer to acquire PolyPeptide Group for CHF 1.46 billion. This acquisition will expand Samsung's portfolio into peptide-based therapeutics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does PolyPeptide Group do?

PolyPeptide Group specializes in the development and manufacturing of peptide-based therapeutics. The company offers services that include custom peptide synthesis and related technologies. It serves a global clientele in the biopharmaceutical sector. It is privately held, operating in Manufacturing, and is based in Switzerland.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.